Clinical Trial

Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 9, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, open phase Ib/II clinical study, which is divided into two phases: dose exploration and efficacy expansion. Participants entering the study will receive HRS-8080 combined with Dalpiciclib Isethionate Tablets therapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-04; most recent amendment 2026-01-07.
Status change: Not Yet Recruiting → Recruiting 2023-12-21
Trial Details
NCT Number NCT06167694
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions Unresectable or Metastatic Breast Cancer
Enrollment 146 participants
Start Date 2023-12-20
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-01-09